NUAK2 and neoplasm: For Nuak2 LOF (Nuak2-CR) studies, we used a CRISPR-Cas9 approach where dual guide RNAs targeting Nuak2 were co-electroporated with tumor-generating PB-IUE plasmids (Fig. 5A).